U.S., Jan. 31 -- ClinicalTrials.gov registry received information related to the study (NCT06801067) titled 'A Study of SER-155 to Treat Diarrhea in People on Immunotherapy' on Jan. 24.
Brief Summary: The purpose of this study is to find out whether SER-155 may be a safe first treatment that causes few or mild side effects for people due to irEC.
Study Start Date: Jan. 24
Study Type: INTERVENTIONAL
Condition:
Diarrhea
Enterocolitis
Intervention:
BIOLOGICAL: SER-155
SER-155 (Cultivated Multi-Strain Live Bacterial Therapeutic, Encapsulated) is an experimental designed ecology of 16 unique, human-commensal bacterial strains encapsulated for oral administration and will be provided by Seres as an investigational drug
Recruitment Status...